Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 12FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Neoplasm Metastasis 1

Interventions

Imiquimod 2Docetaxel 2Celecoxib 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2pembrolizumab 1pasireotide 1gadolinium ethoxybenzyl DTPA 1enzalutamide 1Uterine Myomectomy 1Topotecan 1Tablets 1Sildenafil Citrate 1Reference Standards 1Pentoxifylline 1Mindfulness 1Mass Screening 1Ketoconazole 1Itraconazole 1Hysterectomy 1Hypnosis 1Herpes Zoster Vaccine 1Fecal Microbiota Transplantation 1Exercise 1Estramustine 1Epirubicin 1Doxycycline 1Cryotherapy 1Biopsy, Large-Core Needle 1Azacitidine 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × FED × enzalutamide × Clear all
NCT04116775 2022-06-23

Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.

Portland VA Medical Center

Phase 2 Unknown
32 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡